Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells

PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer

(2016) Andrew J. McPartlin et al.   CANCER

Adipose mesenchymal stromal cells response to ionizing radiation

(2016) Osama Muhammad Maria et al.   CYTOTHERAPY

The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma

(2016) Peter Paximadis et al.   PROSTATE

Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide

(2016) Mark C. Markowski et al.   PROSTATE

Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer

(2016) Marc Gaudet et al.   RADIOTHERAPY AND ONCOLOGY

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer

(2015) Jack Schalken et al.   BJU INTERNATIONAL

Targeting molecular resistance in castration-resistant prostate cancer

(2015) Thenappan Chandrasekar et al.   BMC Medicine

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis

(2015) Jonathan F. Goodwin et al.   CANCER CELL

Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation

(2015) D. E. Spratt et al.   CANCER RESEARCH

ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model

(2015) Mitra Heravi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer

(2015) Wenqing Qi et al.   Oncotarget

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy

(2015) Bo Cao et al.   Oncotarget

The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer

(2014) H. Q. Ta et al.   ENDOCRINE-RELATED CANCER

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer

(2014) Barbara Kahn et al.   International Journal of Biological Sciences

Erratum: Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond DNA Repair: DNA-PK Function in Cancer

(2014) J. F. Goodwin et al.   Cancer Discovery

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SOX10 Ablation Arrests Cell Cycle, Induces Senescence, and Suppresses Melanomagenesis

(2013) J. C. Cronin et al.   CANCER RESEARCH

Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer

(2013) J. Hoffman-Censits et al.   CLINICAL CANCER RESEARCH

Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer

(2013) F. L. T. Al-Ubaidi et al.   CLINICAL CANCER RESEARCH

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer

(2013) Nada Lallous et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells

(2013) Payel Chatterjee et al.   PLoS One

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer

(2013) Javier Guerrero et al.   PROSTATE

A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult

(2013) J. F. Goodwin et al.   Cancer Discovery

Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers

(2013) W. R. Polkinghorn et al.   Cancer Discovery

Androgen Receptor Signaling Fuels DNA Repair and Radioresistance in Prostate Cancer

(2013) J. Bartek et al.   Cancer Discovery

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting

(2013) Bin Xu et al.   Cancer Medicine

Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

(2012) Mitra Heravi et al.   ANTI-CANCER DRUGS

Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs-Dependent DNA Double-Strand Break Repair

(2012) M. Toulany et al.   MOLECULAR CANCER RESEARCH

Characterising the castration-resistant prostate cancer population: a systematic review

(2011) M. Kirby et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer

(2010) K.V. Donkena et al.   CURRENT CANCER DRUG TARGETS

Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

(2010) F Al-Ejeh et al.   ONCOGENE

Cellular senescence: Its role in tumor suppression and aging

(2009) Naoko Ohtani et al.   CANCER SCIENCE

Celastrol Potentiates Radiotherapy by Impairment of DNA Damage Processing in Human Prostate Cancer

(2009) Yao Dai et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Antagonistic interaction between bicalutamide™ (Casodex®) and radiation in androgen-positive prostate cancer LNCaP cells

(2009) Laurent Quéro et al.   PROSTATE